Gofen & Glossberg’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $52.6M | Sell |
325,692
-2,086
| -0.6% | -$320K | 1.35% | 18 |
|
|
2022
Q3 | $44M | Buy |
327,778
+108
| +0% | +$15.5K | 1.24% | 18 |
|
|
2022
Q2 | $50.2M | Sell |
327,670
-6,205
| -2% | -$948K | 1.33% | 18 |
|
|
2022
Q1 | $54.1M | Sell |
333,875
-1,983
| -0.6% | -$288K | 1.23% | 18 |
|
|
2021
Q4 | $45.5M | Buy |
335,858
+20,573
| +7% | +$2.43M | 0.98% | 29 |
|
|
2021
Q3 | $34M | Buy |
315,285
+19,353
| +7% | +$2.21M | 0.8% | 31 |
|
|
2021
Q2 | $33.3M | Buy |
295,932
+11,619
| +4% | +$1.31M | 0.79% | 32 |
|
|
2021
Q1 | $30.8M | Buy |
284,313
+22,943
| +9% | +$2.45M | 0.79% | 33 |
|
|
2020
Q4 | $28M | Buy |
261,370
+12,558
| +5% | +$1.21M | 0.77% | 33 |
|
|
2020
Q3 | $21.8M | Buy |
248,812
+12,355
| +5% | +$1.16M | 0.67% | 43 |
|
|
2020
Q2 | $23.2M | Buy |
236,457
+10,575
| +5% | +$931K | 0.78% | 35 |
|
|
2020
Q1 | $17.2M | Buy |
225,882
+14,416
| +7% | +$1.23M | 0.67% | 45 |
|
|
2019
Q4 | $18.7M | Sell |
211,466
-2,368
| -1% | -$197K | 0.6% | 48 |
|
|
2019
Q3 | $16.2M | Buy |
213,834
+21,359
| +11% | +$1.46M | 0.55% | 53 |
|
|
2019
Q2 | $14M | Buy |
192,475
+23,193
| +14% | +$1.82M | 0.48% | 61 |
|
|
2019
Q1 | $13.6M | Sell |
169,282
-5,720
| -3% | -$468K | 0.48% | 62 |
|
|
2018
Q4 | $16.1M | Sell |
175,002
-2,638
| -1% | -$232K | 0.64% | 49 |
|
|
2018
Q3 | $16.8M | Buy |
177,640
+1,060
| +0.6% | +$101K | 0.58% | 53 |
|
|
2018
Q2 | $16.4M | Sell |
176,580
-5,536
| -3% | -$541K | 0.61% | 53 |
|
|
2018
Q1 | $17.2M | Sell |
182,116
-6,614
| -4% | -$727K | 0.65% | 49 |
|
|
2017
Q4 | $18.3M | Sell |
188,730
-6,368
| -3% | -$600K | 0.65% | 49 |
|
|
2017
Q3 | $17.3M | Sell |
195,098
-8,735
| -4% | -$665K | 0.64% | 51 |
|
|
2017
Q2 | $14.8M | Sell |
203,833
-8,605
| -4% | -$578K | 0.56% | 58 |
|
|
2017
Q1 | $13.8M | Sell |
212,438
-3,249
| -2% | -$204K | 0.54% | 61 |
|
|
2016
Q4 | $13.5M | Sell |
215,687
-9,134
| -4% | -$558K | 0.55% | 61 |
|
|
2016
Q3 | $14.2M | Sell |
224,821
-7,933
| -3% | -$514K | 0.59% | 55 |
|
|
2016
Q2 | $14.4M | Sell |
232,754
-5,198
| -2% | -$317K | 0.6% | 52 |
|
|
2016
Q1 | $13.6M | Buy |
237,952
+24,584
| +12% | +$1.37M | 0.58% | 55 |
|
|
2015
Q4 | $12.6M | Sell |
213,368
-33,471
| -14% | -$1.93M | 0.55% | 59 |
|
|
2015
Q3 | $13.4M | Sell |
246,839
-4,842
| -2% | -$315K | 0.61% | 51 |
|
|
2015
Q2 | $16.9M | Sell |
251,681
-1,379
| -0.5% | -$90K | 0.71% | 43 |
|
|
2015
Q1 | $14.8M | Sell |
253,060
-3,148
| -1% | -$190K | 0.64% | 47 |
|
|
2014
Q4 | $16.8M | Sell |
256,208
-3,099
| -1% | -$195K | 0.72% | 42 |
|
|
2014
Q3 | $15M | Sell |
259,307
-5,864
| -2% | -$326K | 0.66% | 44 |
|
|
2014
Q2 | $15M | Sell |
265,171
-17,038
| -6% | -$894K | 0.66% | 45 |
|
|
2014
Q1 | $14.4M | Buy |
282,209
+13,147
| +5% | +$664K | 0.67% | 44 |
|
|
2013
Q4 | $14.2M | Sell |
269,062
-13,109
| -5% | -$644K | 0.67% | 45 |
|
|
2013
Q3 | $12.6M | Buy |
282,171
+905
| +0.3% | +$40.1K | 0.65% | 48 |
|
|
2013
Q2 | $11.6M | Buy |
+281,266
| New | +$12.3M | 0.63% | 50 |
|
Other funds holding ABBV
AWA
Gofen & Glossberg's ABBV Position: Q4 2022 in Review
Gofen & Glossberg reduced its AbbVie (ABBV) stake by 0.64% in Q4 2022, selling an estimated $320K and leaving 325,692 shares worth $52.6M. The position accounts for 1.35% of the portfolio, ranked #18.
Gofen & Glossberg first reported a position in ABBV in Q2 2013 and has held it in 39 quarters since. The position peaked at $54.1M in Q1 2022. 3,168 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.
- Gofen & Glossberg held 325,692 shares of AbbVie worth $52.6M as of Q4 2022.
- Gofen & Glossberg sold 2,086 AbbVie shares in Q4 2022, an estimated $320K.
- AbbVie made up 1.35% of Gofen & Glossberg's portfolio in Q4 2022, its #18 holding.
- Gofen & Glossberg first reported a position in AbbVie in Q2 2013 and has held it in 39 quarters since.
- Gofen & Glossberg's AbbVie position peaked at $54.1M in Q1 2022.
- 3,168 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.
Based on Gofen & Glossberg's 13F filing for Q4 2022, filed 13 Jan 2023.